MK-2206 + paclitaxel

MK-2206 + paclitaxel is a combination therapy involving the oral allosteric Akt inhibitor MK-2206 and the chemotherapy agent paclitaxel. MK-2206 selectively inhibits Akt, a key signaling protein involved in cancer cell growth, survival, and metabolism. Paclitaxel is a microtubule-stabilizing agent that disrupts mitosis and induces apoptosis in cancer cells. The combination has shown synergistic anticancer effects in preclinical models and clinical trials for various solid tumors, including breast, gastric, and ovarian cancers[2][3][5]. Clinical studies have demonstrated that this combination is generally safe and well tolerated at recommended doses (e.g., MK-2206 135 mg weekly with paclitaxel 80 mg/m² weekly), with evidence of antitumor activity even in patients previously treated with taxanes or HER2-directed therapies[1][3][5].